{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:50:05Z","timestamp":1782471005922,"version":"3.54.5"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pathologie"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00292-026-01561-y","type":"journal-article","created":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T12:29:43Z","timestamp":1777552183000},"page":"254-261","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Diagnostische und pr\u00e4diktive Molekularpathologie des Urothelkarzinoms","Diagnostic and predictive molecular pathology of urothelial carcinoma"],"prefix":"10.1007","volume":"47","author":[{"given":"Sebastian","family":"Rauch","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-7676","authenticated-orcid":false,"given":"Fabienne","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arndt","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"issue":"3","key":"1561_CR1","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S0002-9440(10)65318-7","volume":"154","author":"A Hartmann","year":"1999","unstructured":"Hartmann\u00a0A, Moser\u00a0K, Kriegmair\u00a0M et\u00a0al (1999) Frequent genetic alterations in simple urothelial hyperplasias of the bladder in patients with papillary urothelial carcinoma. Am J Pathol 154(3):721\u2013727","journal-title":"Am J Pathol"},{"issue":"12","key":"1561_CR2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1097\/00000478-199812000-00001","volume":"22","author":"JI Epstein","year":"1998","unstructured":"Epstein\u00a0JI, Amin\u00a0MB, Reuter\u00a0VR et\u00a0al (1998) The World Health Organization\/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 22(12):1435\u20131448","journal-title":"Am J Surg Pathol"},{"issue":"7","key":"1561_CR3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1097\/PAS.0000000000001450","volume":"44","author":"TL Lotan","year":"2020","unstructured":"Lotan\u00a0TL, Tomlins\u00a0SA, Bismar\u00a0TA et\u00a0al (2020) Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers. I. Molecular Biomarkers in Prostate Cancer. Am J Surg Pathol 44(7):e15\u2013e29","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"1561_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nrc3817","volume":"15","author":"MA Knowles","year":"2015","unstructured":"Knowles\u00a0MA, Hurst\u00a0CD (2015) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15(1):25\u201341","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"1561_CR5","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.humpath.2009.07.002","volume":"41","author":"KB Hodges","year":"2010","unstructured":"Hodges\u00a0KB, Lopez-Beltran\u00a0A, Davidson\u00a0DD et\u00a0al (2010) Urothelial dysplasia and other flat lesions of the urinary bladder: clinicopathologic and molecular features. Hum Pathol 41(2):155\u2013162","journal-title":"Hum Pathol"},{"issue":"1","key":"1561_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00292-024-01385-8","volume":"46","author":"F Lange","year":"2025","unstructured":"Lange\u00a0F, Hartmann\u00a0A, Eckstein\u00a0M (2025) Urinary bladder: tumor precursors and non-invasive carcinoma. Pathologie (Heidelb) 46(1):21\u201326","journal-title":"Pathologie (Heidelb)"},{"issue":"24","key":"1561_CR7","doi-asserted-by":"publisher","first-page":"7162","DOI":"10.1158\/0008-5472.CAN-13-2498","volume":"73","author":"I Kinde","year":"2013","unstructured":"Kinde\u00a0I, Munari\u00a0E, Faraj\u00a0SF et\u00a0al (2013) TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine. Cancer Res 73(24):7162\u20137167","journal-title":"Cancer Res"},{"issue":"5","key":"1561_CR8","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan\u00a0D, Weinberg\u00a0RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"2","key":"1561_CR9","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.euf.2017.07.004","volume":"5","author":"S Isharwal","year":"2019","unstructured":"Isharwal\u00a0S, Audenet\u00a0F, Drill\u00a0E et\u00a0al (2019) Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma. Eur Urol Focus 5(2):201\u2013204","journal-title":"Eur Urol Focus"},{"issue":"1","key":"1561_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/PAS.0000000000000305","volume":"39","author":"M Zhong","year":"2015","unstructured":"Zhong\u00a0M, Tian\u00a0W, Zhuge\u00a0J et\u00a0al (2015) Distinguishing nested variants of urothelial carcinoma from benign mimickers by TERT promoter mutation. Am J Surg Pathol 39(1):127\u2013131","journal-title":"Am J Surg Pathol"},{"key":"1561_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.705440","volume":"11","author":"Y Hayashi","year":"2021","unstructured":"Hayashi\u00a0Y, Fujita\u00a0K, Netto\u00a0GJ et\u00a0al (2021) Clinical Application of TERT Promoter Mutations in Urothelial Carcinoma. Front Oncol 11:705440","journal-title":"Front Oncol"},{"issue":"15","key":"1561_CR12","doi-asserted-by":"publisher","first-page":"6021","DOI":"10.1073\/pnas.1303607110","volume":"110","author":"PJ Killela","year":"2013","unstructured":"Killela\u00a0PJ, Reitman\u00a0ZJ, Jiao\u00a0Y et\u00a0al (2013) TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S\u00a0A 110(15):6021\u20136026","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1561_CR13","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1111\/his.14206","volume":"77","author":"S Bertz","year":"2020","unstructured":"Bertz\u00a0S, Stohr\u00a0R, Gaisa\u00a0NT et\u00a0al (2020) TERT promoter mutation analysis as a surrogate to morphology and immunohistochemistry in problematic spindle cell lesions of the urinary bladder. Histopathology 77(6):949\u2013962","journal-title":"Histopathology"},{"key":"1561_CR14","doi-asserted-by":"crossref","unstructured":"Weyerer, V., M.\u00a0Eckstein, P.L.\u00a0Strissel, et\u00a0al., TERT Promoter Mutation Analysis of Whole-Organ Mapping Bladder Cancers. Genes (Basel), 2021. 12(2).","DOI":"10.3390\/genes12020230"},{"issue":"2","key":"1561_CR15","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.eururo.2013.08.052","volume":"65","author":"Y Allory","year":"2014","unstructured":"Allory\u00a0Y, Beukers\u00a0W, Sagrera\u00a0A et\u00a0al (2014) Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. Eur Urol 65(2):360\u2013366","journal-title":"Eur Urol"},{"key":"1561_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2023.102530","volume":"115","author":"CM Ascione","year":"2023","unstructured":"Ascione\u00a0CM, Napolitano\u00a0F, Esposito\u00a0D et\u00a0al (2023) Role of FGFR3 in bladder cancer: Treatment landscape and future challenges. Cancer Treat Rev 115:102530","journal-title":"Cancer Treat Rev"},{"key":"1561_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.euros.2025.04.005","volume":"77","author":"M Haas","year":"2025","unstructured":"Haas\u00a0M, Mayr\u00a0R, Sikic\u00a0D et\u00a0al (2025) Clinical and Genomic Landscape of FGFR3 Alterations Across Different Stages of Urothelial Cancer. Eur Urol Open Sci 77:1\u20139","journal-title":"Eur Urol Open Sci"},{"issue":"5_suppl","key":"1561_CR18","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1200\/JCO.2025.43.5_suppl.662","volume":"43","author":"G Iyer","year":"2025","unstructured":"Iyer\u00a0G, Ebi\u00a0H, Cook\u00a0N et\u00a0al (2025) A first-in-human phase 1 study of LY3866288 (LOXO-435), a potent, highly isoform-selective FGFR3 inhibitor (FGFR3i) in advanced solid tumors with FGFR3 alterations: Initial results from FORAGER\u20111. Journal of Clinical Oncology 43(5_suppl):662\u2013662","journal-title":"Journal of Clinical Oncology"},{"key":"1561_CR19","unstructured":"Trials, C. FORAGER-2: A\u00a0Phase\u00a03, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined With Enfortumab Vedotin and Pembrolizumab in Adults With Untreated Locally Advanced or Metastatic Urothelial Carcinoma With an FGFR3 Genetic Alteration. 06.01.2026]; Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT07218380."},{"key":"1561_CR20","doi-asserted-by":"crossref","unstructured":"Weyerer, V., M.\u00a0Eckstein, E.\u00a0Comperat, et\u00a0al., Pure Large Nested Variant of Urothelial Carcinoma (LNUC) Is the Prototype of an FGFR3 Mutated Aggressive Urothelial Carcinoma with Luminal-Papillary Phenotype. Cancers (Basel), 2020. 12(3).","DOI":"10.3390\/cancers12030763"},{"issue":"10","key":"1561_CR21","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1056\/NEJMoa2312117","volume":"390","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Valderrama\u00a0BP, Gupta\u00a0S et\u00a0al (2024) Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer. N\u00a0Engl J Med 390(10):875\u2013888","journal-title":"N Engl J Med"},{"key":"1561_CR22","unstructured":"FDA (2026) FDA approves pembrolizumab with enfortumab vedotin-ejfv for muscle invasive bladder cancer. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer"},{"key":"1561_CR23","unstructured":"Astellas (2025) PADCEV\u2122 Plus Keytruda\u00ae Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility. https:\/\/newsroom.astellas.com\/2025-12-17-PADCEVTM-Plus-KeytrudaTM-Significantly-Improves-Survival-for-Patients-with-Muscle-Invasive-Bladder-Cancer-Regardless-of-Cisplatin-Eligibility. Accessed 6.1.2026"},{"issue":"23","key":"1561_CR24","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1056\/NEJMoa2511648","volume":"393","author":"X Sheng","year":"2025","unstructured":"Sheng\u00a0X, Zeng\u00a0G, Zhang\u00a0C et\u00a0al (2025) Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. N\u00a0Engl J Med 393(23):2324\u20132337","journal-title":"N Engl J Med"},{"issue":"20","key":"1561_CR25","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1200\/JCO.23.01983","volume":"42","author":"N Klumper","year":"2024","unstructured":"Klumper\u00a0N, Tran\u00a0NK, Zschabitz\u00a0S et\u00a0al (2024) NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer. J\u00a0Clin Oncol 42(20):2446\u20132455","journal-title":"J Clin Oncol"},{"issue":"5","key":"1561_CR26","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/his.15130","volume":"84","author":"V Bahlinger","year":"2024","unstructured":"Bahlinger\u00a0V, Branz\u00a0A, Strissel\u00a0PL et\u00a0al (2024) Associations of TACSTD2\/TROP2 and NECTIN-4\/NECTIN\u20114 with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. Histopathology 84(5):863\u2013876","journal-title":"Histopathology"},{"issue":"7","key":"1561_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100753","volume":"38","author":"G Dernbach","year":"2025","unstructured":"Dernbach\u00a0G, Eich\u00a0ML, Dragomir\u00a0MP et\u00a0al (2025) Spatial Expression of HER2, NECTIN4, and TROP\u20112 in Muscle-Invasive Bladder Cancer and Metastases: Implications for Pathological and Clinical Management. Mod Pathol 38(7):100753","journal-title":"Mod Pathol"},{"key":"1561_CR28","unstructured":"FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. 06.01.2026]; Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"1561_CR29","unstructured":"EMA. Product-Information Enhertu. 06.01.2026]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/enhertu-epar-product-information_en.pdf."},{"issue":"22","key":"1561_CR30","doi-asserted-by":"publisher","first-page":"2102","DOI":"10.1056\/NEJMoa2034442","volume":"384","author":"DF Bajorin","year":"2021","unstructured":"Bajorin\u00a0DF, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2021) Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma. N\u00a0Engl J Med 384(22):2102\u20132114","journal-title":"N Engl J Med"},{"issue":"1","key":"1561_CR31","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.24.00340","volume":"43","author":"MD Galsky","year":"2025","unstructured":"Galsky\u00a0MD, Witjes\u00a0JA, Gschwend\u00a0JE et\u00a0al (2025) Adjuvant Nivolumab in High-Risk Muscle-Invasive Urothelial Carcinoma: Expanded Efficacy From CheckMate 274. J\u00a0Clin Oncol 43(1):15\u201321","journal-title":"J Clin Oncol"},{"issue":"1","key":"1561_CR32","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa2401726","volume":"392","author":"AB Apolo","year":"2025","unstructured":"Apolo\u00a0AB, Ballman\u00a0KV, Sonpavde\u00a0G et\u00a0al (2025) Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial Carcinoma. N\u00a0Engl J Med 392(1):45\u201355","journal-title":"N Engl J Med"},{"key":"1561_CR33","unstructured":"EMA. Product-Infomation Keytruda, INN-pembrolizumab. 06.01.2026]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/keytruda-epar-product-information_en.pdf."},{"issue":"22","key":"1561_CR34","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.10.24","volume":"7","author":"M Eckstein","year":"2019","unstructured":"Eckstein\u00a0M, Cimadamore\u00a0A, Hartmann\u00a0A et\u00a0al (2019) PD-L1 assessment in urothelial carcinoma: a practical approach. Ann Transl Med 7(22):690","journal-title":"Ann Transl Med"},{"key":"1561_CR35","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.ejca.2018.11.007","volume":"106","author":"M Eckstein","year":"2019","unstructured":"Eckstein\u00a0M, Erben\u00a0P, Kriegmair\u00a0MC et\u00a0al (2019) Performance of the Food and Drug Administration\/EMA-approved programmed cell death ligand\u20111 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab. Eur J Cancer 106:234\u2013243","journal-title":"Eur J Cancer"},{"issue":"19","key":"1561_CR36","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","volume":"391","author":"T Powles","year":"2024","unstructured":"Powles\u00a0T, Catto\u00a0JWF, Galsky\u00a0MD et\u00a0al (2024) Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer. N\u00a0Engl J Med 391(19):1773\u20131786","journal-title":"N Engl J Med"},{"issue":"4","key":"1561_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/j.eururo.2019.09.006","volume":"77","author":"A Kamoun","year":"2020","unstructured":"Kamoun\u00a0A, de Reynies\u00a0A, Allory\u00a0Y et\u00a0al (2020) A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol 77(4):420\u2013433","journal-title":"Eur Urol"},{"issue":"7693","key":"1561_CR38","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/nature25501","volume":"554","author":"S Mariathasan","year":"2018","unstructured":"Mariathasan\u00a0S, Turley\u00a0SJ, Nickles\u00a0D et\u00a0al (2018) TGFbeta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature 554(7693):544\u2013548","journal-title":"Nature"},{"issue":"1","key":"1561_CR39","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1158\/1078-0432.CCR-13-1992","volume":"20","author":"JS Ross","year":"2014","unstructured":"Ross\u00a0JS, Wang\u00a0K, Gay\u00a0LM et\u00a0al (2014) A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res 20(1):68\u201375","journal-title":"Clin Cancer Res"},{"key":"1561_CR40","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.humpath.2018.03.015","volume":"77","author":"S Isharwal","year":"2018","unstructured":"Isharwal\u00a0S, Huang\u00a0H, Nanjangud\u00a0G et\u00a0al (2018) Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma. Hum Pathol 77:63\u201369","journal-title":"Hum Pathol"},{"issue":"18","key":"1561_CR41","doi-asserted-by":"publisher","first-page":"5123","DOI":"10.1158\/1078-0432.CCR-20-4175","volume":"27","author":"CE Chu","year":"2021","unstructured":"Chu\u00a0CE, Sjostrom\u00a0M, Egusa\u00a0EA et\u00a0al (2021) Heterogeneity in NECTIN4 Expression Across Molecular Subtypes of Urothelial Cancer Mediates Sensitivity to Enfortumab Vedotin. Clin Cancer Res 27(18):5123\u20135130","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1561_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.32074\/1591-951X-937","volume":"116","author":"M Brunelli","year":"2024","unstructured":"Brunelli\u00a0M, Gobbo\u00a0S, Malpeli\u00a0G et\u00a0al (2024) TROP\u20112, NECTIN\u20114 and predictive biomarkers in sarcomatoid and rhabdoid bladder urothelial carcinoma. Pathologica 116(1):55\u201361","journal-title":"Pathologica"},{"issue":"12","key":"1561_CR43","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","volume":"384","author":"T Powles","year":"2021","unstructured":"Powles\u00a0T, Rosenberg\u00a0JE, Sonpavde\u00a0GP et\u00a0al (2021) Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma. N\u00a0Engl J Med 384(12):1125\u20131135","journal-title":"N Engl J Med"},{"issue":"1","key":"1561_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.eururo.2022.09.030","volume":"83","author":"MJ Shi","year":"2023","unstructured":"Shi\u00a0MJ, Fontugne\u00a0J, Moreno-Vega\u00a0A et\u00a0al (2023) FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias. Eur Urol 83(1):70\u201381","journal-title":"Eur Urol"},{"issue":"21","key":"1561_CR45","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1056\/NEJMoa2308849","volume":"389","author":"Y Loriot","year":"2023","unstructured":"Loriot\u00a0Y, Matsubara\u00a0N, Park\u00a0SH et\u00a0al (2023) Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma. N\u00a0Engl J Med 389(21):1961\u20131971","journal-title":"N Engl J Med"},{"issue":"6","key":"1561_CR46","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.celrep.2019.04.048","volume":"27","author":"CC Guo","year":"2019","unstructured":"Guo\u00a0CC, Majewski\u00a0T, Zhang\u00a0L et\u00a0al (2019) Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep 27(6):1781\u20131793","journal-title":"Cell Rep"},{"issue":"1","key":"1561_CR47","doi-asserted-by":"publisher","first-page":"75","DOI":"10.21873\/invivo.12234","volume":"35","author":"D Goutas","year":"2021","unstructured":"Goutas\u00a0D, Tzortzis\u00a0A, Gakiopoulou\u00a0H et\u00a0al (2021) Contemporary Molecular Classification of Urinary Bladder Cancer. In Vivo 35(1):75\u201380","journal-title":"In Vivo"}],"container-title":["Die Pathologie"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00292-026-01561-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00292-026-01561-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T10:08:41Z","timestamp":1782468521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00292-026-01561-y"}},"subtitle":["Bestandsaufnahme und Ausblick in die Zukunft","Current status and outlook for the future"],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":47,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1561"],"URL":"https:\/\/doi.org\/10.1007\/s00292-026-01561-y","relation":{},"ISSN":["2731-7188","2731-7196"],"issn-type":[{"value":"2731-7188","type":"print"},{"value":"2731-7196","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Hartmann: Honorare von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Roche, 3DHistotech; Beratungsgeb\u00fchren von Abbvie, AstraZeneca, Biontech, BMS, Boehringer Ingelheim, Cepheid, Diaceutics, Gilead, Illumina, Ipsen, Janssen, Lilly, MSD, Nanostring, Novartis, Qiagen, QUIP GmbH, Roche, 3DHistotech; Forschungsf\u00f6rderung von AstraZeneca, Biontech, Cepheid, Gilead, Illumina, Janssen, Nanostring, Qiagen, QUIP GmbH, Roche. M.\u00a0Eckstein: Honorare und Reisekosten von MSD, AstraZeneca, Janssen-Cilag, Cepheid, Roche, Astellas, Diaceutics, Owkin, BMS; Forschungsf\u00f6rderung von AstraZeneca, Janssen-Cilag, STRATIFYER, Cepheid, Roche, Gilead, Owkin, QUIP GmbH; Beratungsgeb\u00fchren von Diaceutics, MSD, AstraZeneca, Janssen-Cilag, GenomicHealth, Owkin, BMS. S.\u00a0Rauch und F.\u00a0Lange geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}